BTSGNASDAQ Global Select· United States· Healthcare
This company has a mixed profile, with supportive analyst views and a positive price trend, although its profitability is thin.
Quant Score on a 1–100 scale, computed Oct 24, 10:01 AM EDT from the data shown on this page. It describes the company’s current profile — it is not a price prediction or a recommendation. How it’s calculated
Tap any area to see the numbers it is based on.
The case for, the case against, and what to watch.
Is the business growing, profitable and able to carry its debt?
Is the stock reasonably priced?
The stock looks fully priced — investors are already paying for good results.
See how it stacks up on quality, growth, valuation, risk and momentum.
Is this a profitable, well-run business?
Weak. Strongest signal: free cash flow / operating cash flow at 79%. Weakest: operating margin (ttm) at 3.3%.
| Input | Value | Points /10 |
|---|---|---|
| Return on equity (TTM) | 15.2% | 4.1 |
| Return on invested capital (TTM) | 8.9% | 2.3 |
| Operating margin (TTM) | 3.3% | 0.0 |
| Net margin (TTM) | 2.0% | 0.0 |
| Free cash flow / operating cash flow | 79% | 8.2 |
“n/a” means the data wasn’t available; missing inputs are left out of the average, never counted as zero.
Is this a financially healthy business?
Adequate. Strongest signal: piotroski f-score at 7/9. Weakest: interest coverage at 3.1x.
| Input | Value | Points /10 |
|---|---|---|
| Piotroski F-Score | 7/9 | 8.3 |
| Altman Z-Score | 4.67 | 6.8 |
| Debt / Equity | 1.17 | 4.4 |
| Current ratio | 1.6x | 4.6 |
| Interest coverage | 3.1x | 0.6 |
“n/a” means the data wasn’t available; missing inputs are left out of the average, never counted as zero.
Is the stock expensive?
Fully priced. Strongest signal: peg at 0.13. Weakest: dcf upside at -85.7%.
| Input | Value | Points /10 |
|---|---|---|
| P/E (TTM) | 42.0x | 3.7 |
| PEG | 0.13 | 10.0 |
| Price / FCF | 29.6x | 6.3 |
| EV / EBITDA | 21.5x | 5.8 |
| DCF upside | -85.7% | 0.0 |
“n/a” means the data wasn’t available; missing inputs are left out of the average, never counted as zero.
Is the company growing?
Modest growth. Strongest signal: net income growth (fy) at 1155.6%. Weakest: gross margin at 12.4%.
| Input | Value | Points /10 |
|---|---|---|
| Revenue growth (FY) | 14.6% | 4.4 |
| Net income growth (FY) | 1155.6% | 10.0 |
| Revenue CAGR (3Y) | 18.7% | 6.2 |
| Forward revenue growth | 19.0% | 6.3 |
| Gross margin | 12.4% | 0.0 |
“n/a” means the data wasn’t available; missing inputs are left out of the average, never counted as zero.
Is the stock price showing strength?
Positive. Strongest signal: trend alignment (50/200 sma) at 3/3. Weakest: macd histogram at -0.18.
| Input | Value | Points /10 |
|---|---|---|
| Trend alignment (50/200 SMA) | 3/3 | 10.0 |
| RSI (14) | 46.6 | 10.0 |
| MACD histogram | -0.18 | 2.0 |
| Signal consensus | Neutral | 4.5 |
“n/a” means the data wasn’t available; missing inputs are left out of the average, never counted as zero.
What do professional analysts think?
Positive. Strongest signal: analyst buy share at 100%.
| Input | Value | Points /10 |
|---|---|---|
| Analyst buy share | 100% | 10.0 |
| Target upside | 28.9% | 7.8 |
| 90-day rating revisions | 0↑ / 0↓ | 5.0 |
“n/a” means the data wasn’t available; missing inputs are left out of the average, never counted as zero.
What could go wrong?
High risk. Strongest signal: largest 1y drawdown at -24%. Weakest: beta (vs. market) at 1.88.
| Input | Value | Points /10 |
|---|---|---|
| Beta (vs. market) | 1.88 | 0.9 |
| Price volatility (1Y, annualised) | 44% | 3.8 |
| Largest 1Y drawdown | -24% | 6.3 |
| Net debt / EBITDA | 2.9x | 2.8 |
“n/a” means the data wasn’t available; missing inputs are left out of the average, never counted as zero.
A formula-based estimate from projected cash flows. Small changes in assumptions move it a lot — treat it as one input, not a price the stock will reach.
Range $64.00–$90.00. Analysts' 12-month opinions; they are frequently wrong and are not our forecast.
Source: Financial Modeling Prep · P/E trailing twelve months; history from annual filings · USD · data as of Oct 24, 2026
Revenue is what customers paid the company. Over 4 years it has grown about 18% a year on average.
Net income is the profit left after all costs and taxes. Over 4 years it has grown about 40% a year on average.
Cash the business generates after investing in itself — what can fund dividends, buybacks or growth. Over 4 years it has grown about 17% a year on average.
Share of sales left after the direct cost of products.
Share of sales left after running the business.
Share of sales kept as profit.
Debt is high compared with shareholders' equity — worth watching.
Returns on invested money are around average.
Profits cover interest payments comfortably.
Source: Financial Modeling Prep · annual filings FY2021–FY2025; margins and ratios trailing twelve months · USD · data as of Oct 24, 2026
